NRG Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response Adapted Treatment versus Standard of Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma Adult CIRB - Late Phase Emphasis Active Available to Open